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based on primary ICD-9-CM discharge diagnosis of ICH
(431.xx). Patient-level information included demographics
(including race/ethnicity: White, Black, Hispanic, Asian), hospi-
tal characteristics, comorbidities, primary payer, admission
source, discharge destination, DRG, length of stay (LOS), and
hospital charges. Costs were estimated by applying hospital-
speciﬁc cost-to-charge ratios to charges. Adjusted LOS and cost
(controlling for age, in-hospital mortality, and other covariates)
by race/ethnicity were estimated using multivariate least-squares
regression. RESULTS: Black, Hispanic, and Asian patients with
a primary diagnosis of ICH at discharge were signiﬁcantly
younger, on average, than White patients (73.5 vs. 61.2, 63.9,
and 67.9 years, respectively; p < 0.01 for all comparisons). Black
and Hispanic patients experienced longer hospital stays (p <
0.01) and incurred higher costs (p < 0.01), on average, than
White patients. Among Black and Hispanic patients, adjusted
length of stay (mean costs) per discharge were approximately 2.3
days ($1400) and 1.7 ($3400) higher, respectively, as compared
to White patients. Asian patients had longer adjusted stays (2.6
additional days, p < 0.01) and higher costs ($830, p < 0.31).
CONCLUSIONS: There are meaningful differences in length of
stay and cost of ICH hospitalizations among patients with dif-
ferent race/ethnicity. Improved acute treatment of stroke in this
high-risk population may help to improve overall outcomes in
these subgroups.
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OBJECTIVES: To assess the association between
overweight/obesity and employment to population ratio (E/P
Ratio), hourly wage, and annual income in the U.S. METHODS:
Adults (age 18–64) in the 2000–2002 Medical Expenditure 
Panel Survey (MEPS) were classiﬁed as normal weight
(BMI:18.5–24.9), overweight (BMI:25–29.9), and obese (BMI:
>= 30). Underweight (BMI < 18.5) individuals were excluded.
E/P ratio, hourly wage, annual income, and poverty status of the
overweight and obese adults were compared to that of the
normal weight adults, respectively, adjusting for demographic
characteristics using a stratiﬁcation matching method. MEPS
sampling weights were applied to ensure nationally representa-
tive estimates. The analyses were also conducted for population
subgroups deﬁned by gender, race, ethnicity, and physical activ-
ity. RESULTS: The study sample includes 35,989 adults, with
13,744 normal weight, 13,321 overweight, and 8,924 obese. The
E/P ratio was 87.1% for the overweight sample, 1.8% higher (p
< 0.01) than the normal weight sample; and 82.4% for the obese
sample, 1.7% lower (p < 0.01) than the normal weight sample.
The obese sample made $1.63 less per hour (p < 0.01), and
$3338 less annually compared to the normal weight sample (p
< 0.01). Compared to the normal weight sample, obese adults
were more likely to be poor. No signiﬁcant difference of annual
income and poverty level were found between the overweight
and the normal weight sample. Systematic differences between
different population subgroups were found. CONCLUSIONS:
Obese adults are less likely to be employed, have lower annual
incomes and hourly wages, and are more likely to be poor than
normal weight adults.
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OBJECTIVE: To examine the incidence of overactive bladder
(OAB)-related clinical events for elderly patients receiving phar-
macotherapy compared with those receiving non-pharmacologic
management. METHODS: Data were obtained from the Phar-
Metrics Patient-Centric Database on continuously beneﬁt-
eligible patients aged ≥65 years diagnosed with OAB between
January 2002 and December 2003. Patients were categorized
into 2 cohorts: those receiving pharmacotherapy, including long-
acting tolterodine, or immediate- or extended-release oxybutynin
and those receiving non-pharmacologic management. Patients
were matched 1 :1 by the estimated propensity score for OAB
pharmacotherapy using a logistic regression model that included
selected demographic and clinical characteristics. The incidence
of clinical events, including assessment of depression, urinary
tract infections (UTIs), and falls or fractures was evaluated.
Crude event rates were reported, as well as the risk of an event
using Cox proportional hazards models adjusting for important
demographic and clinical characteristics. RESULTS: A total of
1681 matched pairs were identiﬁed. Mean ± SD age was 78 ± 8
years; 60% were women. After matching, differences in baseline
patient characteristics between cohorts were not signiﬁcant. The
incidence of depression (10.2% for pharmacotherapy vs 11.0%
for non-pharmacologic management; p = NS) and fractures
(8.6% vs 10.1%; p = NS) was numerically lower in the drug-
treated cohort, and the incidence of UTI was signiﬁcantly lower
(28.1% vs 36.5%; p < 0.0001). Adjusted rates using Cox pro-
portional hazards models were similar, with no difference in the
risk of depression (hazard ratio [HR] = 0.980; 95% conﬁdence
interval [CI], 0.795–1.208; p = NS) or fractures (HR = 0.863;
95% CI, 0.691–1.079; p = NS) between the cohorts, and the risk
of UTI was 28% lower among pharmacotherapy patients (HR =
0.718; 95% CI, 0.636–0.810; p < 0.0001). CONCLUSIONS:
Pharmacotherapy may impart selected clinical beneﬁts for some
elderly patients with OAB compared with non-pharmacologic
management. Careful consideration should be given to the selec-
tion of treatment approaches in this high-risk population.
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OBJECTIVES: We examined the effects of statin prescription
drug copayments and statin adherence on cardiovascular uti-
lization patterns, medical and prescription drug expenditures
and other outcomes of statin therapy. METHODS: The
2001–2003 MarketScan database was used to study the health
care utilization and expenditure patterns of continuously
enrolled statin users in employer sponsored health plans. We
analyzed the utilization patterns of 93,296 continuing users who
had previously ﬁlled at least one statin prescription in 2000 and
24,128 users who were new to statin therapy in the ﬁrst half of
2001. A two-stage estimation approach consisted of a multi-
variate logit model estimating the relationship between copay-
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ments and adherence from June 2001 through December 2002.
Generalized Linear Models were estimated to examine the effects
of adherence on utilization patterns and expenditures in 2003.
RESULTS: Higher copayments led to lower levels of statin
adherence (Odds Ratio 0.75 p < 0.01 prevalent users, 0.72 p <
0.01 new users). For continuing users of statins higher levels of
statin adherence were associated with fewer adverse events: hos-
pitalizations (OR: 0.419 p = 0.01), cardiovascular hospitaliza-
tions (OR: 0.425 p = 0.046) and ER visits (OR: 0.219 p < 0.01).
Adherent patients had a larger number of physician ofﬁce visits
(OR: 14.84 p < 0.01 continuing users, 5.07 p < 0.01 new users)
and higher prescription drug expenditures (partial elasticity
0.204 p < 0.01 continuing users, 0.314 p < 0.01 new users).
However, medical expenditures and total (medical plus pre-
scription drug) expenditures for these patients were not signiﬁ-
cantly different from nonadherent patients. CONCLUSIONS:
Statin copayments serve as a ﬁnancial barrier to statin adherence.
Lower levels of adherence are associated with adverse cardio-
vascular and medical outcomes for patients remaining on statin
therapy. Policymakers and plan managers should consider effects
of higher statin copayments on adherence, utilization patterns
and clinical events.
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OBJECTIVES: Investigate how selection criteria and statistical
model speciﬁcations affect comparisons of alternative medica-
tions using retrospective database analyses. METHODS: Data
from the Medi-Cal Program were used to conduct a series of
head-to-head comparisons of alternative antipsychotics to test
the sensitivity of results to sample selection and model speciﬁ-
cation. OLS models were estimated for duration of therapy
deﬁned based on breaks in therapy >15 days. Five models were
compared: (1) a baseline model with only demographic inde-
pendent variables and selection criteria limited to age (18–100)
and prior eligibility >6 months; (2) screening for one year of
post-treatment data; (3) screening for schizophrenia; (4) addition
of prior diagnoses and utilization; and (5) addition of indepen-
dent variables for episode type. RESULTS: The baseline sample
consisted of 263,206 episodes. Average unadjusted days of
therapy for typical antipsychotics, olanzapine, risperidone and
quetiapine were 63, 138, 143 and 131, respectively. Model 1
found longer duration for all atypical antipsychotics relative to
conventional drugs (63–67 days). Risperidone exhibited longer
duration relative to olanzapine (+6 days, p < 0.0001) while olan-
zapine duration exceeded quetiapine by 8 days (p < 0.0001).
Duration for typicals increased from 63 days to 112 days in the
schizophrenia analysis (N = 70,650), reducing the estimated dif-
ferences favoring atypicals to 29–32 days (p < 0.0001). Adding
independent variables for prior utilization and diagnostic mix
reversed risperidone’s advantage over olanzapine from +6 to -4
days (p < 0.0001). Results favoring quetiapine over olanzapine
in duration of therapy on all antipsychotics was reversed from
+4 to +16 days to -3 days when covariates for episode type were
included in the model. CONCLUSIONS: Differences in duration
of antipsychotic therapy exist across diagnostic group and
episode type. Differences also exist in the diagnostic and episode
mix across drugs. Therefore, disaggregated patient samples and
expanded model speciﬁcations provide more accurate estimates
of differences in treatment duration.
MENTAL HEALTH
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NATIONAL TRENDS IN THE DIAGNOSIS OF ATTENTION-
DEFICIT/HYPERACTIVITY DISORDER AND USE OF
STIMULANTS AMONG CHILDREN IN THE UNITED STATES,
1993–2003
Toh S
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OBJECTIVES: To estimate the prevalence of diagnosis of atten-
tion-deﬁcit/hyperactivity disorder (ADHD) and use of stimulants
for children aged 3–18 years in the US ambulatory settings.
METHODS: Data from the National Ambulatory Medical Care
Survey (NAMCS) and the National Hospital Ambulatory
Medical Care Survey (NHAMCS) 1993–2003 were used. The
main outcome measures were annual visits with diagnosis of
ADHD, visits with prescription of stimulants, and proportion of
stimulants prescribed in visits with diagnosis of ADHD. Diag-
nosis of ADHD was determined using ICD-9-CM code 314.
Stimulants (methylphenidate, dexmethylphenidate, pemoline,
and amphetamine compounds) were identiﬁed by generic codes.
95% conﬁdence intervals were calculated and PROC SUR-
VEYFREQ in SAS 9.1 was used to account for the complex sam-
pling designs of these surveys. The results were weighted to
reﬂect national estimates. RESULTS: Outpatient visits made by
children 3–18 years of age increased from 131 (95% CI:
109–153) million in 1993 to 165 (137–192) million in 2003.
Diagnosis of ADHD increased 127%, from 3.2 (1.3–5.2) million
to 7.4 (5.2–9.5) million, accounted for 2.5% (1.0%–3.9%) and
4.5% (3.4%–5.6%) of all visits made by children in 1993 and
2003, respectively. Visits with stimulants prescribed jumped
from 2.7 (0.9–4.5) million in 1993 to 6.6 (4.5–8.7) million in
2003. Proportion of stimulant use in children doubled over this
period, from 2.1% (0.7%–3.4%) to 4.0% (3.0%–5.0%). Pro-
portion of children with ADHD treated with stimulants ranged
from 64.0% in 1997 to 77.3% in 1996, with an average of
70.4% (68.1%–72.8%) over the years studied. CONCLU-
SIONS: There was a steady growth in prevalence of ADHD and
stimulant use among children aged 3–18 years in the US between
1993 and 2003. Approximately 70% children with ADHD were
treated with stimulants. As appropriateness of treatment could
not be determined in the current databases, whether this per-
centage represents overutilization of underutilization of stimu-
lants merits further studies.
MH2
USE PATTERNS AND OUTCOMES ASSOCIATED WITH
TYPICAL DEPOT ANTIPSYCHOTIC AGENTS IN THE
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OBJECTIVE: To assess the clinical characteristics and medica-
tion patterns of patients with schizophrenia treated with typical
depot antipsychotics compared with oral antipsychotics in the
usual care setting in Australia. METHODS: This was a prospec-
tive, single-site, observational study of 348 subjects with schiz-
ophrenia assessed at six-month intervals over three years. Data
were collected via face-to-face interviews by research personnel
and from external information systems to evaluate resource util-
isation. The two groups were compared for demographic and
clinical characteristics at baseline, co-therapy use, rate and
average length of stay (ALoS) of hospitalisation over the three
years. Analysis of variance was used to compare continuous vari-
ables, whereas the chi-square test was used for categorical out-
comes. RESULTS: A total of 144 and 179 patients were treated
